The Generic and Biosimilar Medicines Association announced it has appointed Ms Jane Halton AO PSM as its inaugural...
Jane Halton appointed as GBMA Chair
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Emily Dwyer
Emily provides broad paralegal services including litigation support services, legal research, IP monitoring and tracking services, and document management.
A self professed “legal junkie” she loves exploring legal arguments and is excited about new legal developments.
See Emily's full profile
Pearce IP BioBlast™: w/e 04 December 2020
24 Nov 20 | Novartis released its annual report 'Meet Novartis Management 2020'. In the report, Novartis announced...
Pearce IP BioBlast™: w/e 27 November 2020
22 Nov 20 | Innovent released results of Ph III trials of Tyvyt® (sintilimab) with Byvasda® (biosimilar bevacizumab)...
Preliminary discovery not justified by fear of a future product launch
In Pfizer Ireland Pharmaceuticals v Sandoz Pty Ltd [2020] FCA 1648, the Federal Court of Australia declined to order...
Pearce IP BioBlast™: w/e 20 November 2020
Significant biosimilar activities this week include 15 Nov 20 | US | Genentech filed a complaint against Centus...
Pearce IP BioBlast™: w/e 13 November 2020
Significant biosimilar activities this week include 05 Nov 20 | Formycon announced its BLA resubmission strategy for...
Pearce IP BioBlast™: w/e 06 November 2020
Significant biosimilar activities this week include 05 Nov 20 | Teva released its Q3 2020 financial results, reporting...
Pharma Intelligence announces Global Generics & Biosimilars Digital Awards Winners
Pharma Intelligence announced the Global Generics & Biosimilars Digital Awards Winners. Alvogen, Accord...
Pearce IP BioBlast™: w/e 30 October 2020
Significant biosimilar activities this week include 22 Oct 20 | Ph III clinical trials of FYB202...
Pearce IP BioBlast™: w/e 23 October 2020
Significant biosimilar activities this week include 15 Oct 20 | Henlius and Essex announced they have entered into a...
Pearce IP BioBlast™: w/e 16 October 2020
Significant biosimilar activities this week include 09 Oct 20 | CN | Innovent and Eli Lilly jointly announced China's...
MHRA Releases Post-Brexit Biosimilar Guidelines
Next year, the UK will conclude its transition from the EU, with the regulation of all medicines and devices to be...
Pearce IP BioBlast™: w/e 09 October 2020
Significant biosimilar activities this week include 05 Oct 20 | Medicure announced it has entered a License,...
Pearce IP BioBlast™: w/e 02 October 2020
Significant biosimilar activities this week include 28 Sep 20 | Innovent announced its Ph III trial of Byvasda®...
TGA Approves Second Registered Medicinal Cannabis Product
The TGA has approved GW Pharma's Epidyolex® (cannabidiol) as an adjunctive therapy for seizures associated with...
Pearce IP BioBlast™: w/e 25 September 2020
Significant biosimilar activities this week include 21 Sep 20 | EU | Alexion announced it has received a positive...